Verisante Technology, Inc.(http://www.verisante.com/) (TSX
VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or
"Verisante"), a leader in cancer detection technology, announced today
that Thomas Braun, the Company's President & CEO, has been invited to
speak at the International Society of Radiographers & Radiological
Technologists (ISRRT) World Congress and the Canadian Association of
Medical Radiation Technologists (CAMRT's) Annual General Conference on
June 9, 2012 at 10:30 am.
"Technologists and other frontline health care workers may be the key
to alleviating long wait times and bottlenecks that stem from a
shortage of overworked specialist physicians," said Mr. Braun. "The
adoption of new technologies such as the Aura? for skin cancer
detection can save the health care system time and money while helping
patients with improved outcomes and reduced wait times."
Verisante Aura? is indicated for use for the evaluation of skin
lesions that may be clinically suspicious for melanoma, squamous cell
carcinoma and/or basal cell carcinoma when a medical professional
chooses to obtain additional information to rule out one of the above
conditions before making a final decision to biopsy. With Verisante
Aura? licensed to be used by any medical professional, medical
radiation technologists could operate the device and send the results
back to doctors, funneling only the most critical cases along to a
doctor for biopsy or for referral to a dermatologist. With membership
of approximately 12,000, CAMRT members work in over 1000 medical
imaging locations in hospitals and private imaging clinics across
Mr. Braun will present during the Canadian Innovation Showcase, a
session of the joint Congress and Conference that highlights Canadian
companies who are breaking new ground with revolutionary approaches to
diagnostic imaging and therapeutic treatment.
"We are excited to be hosting the Canadian Innovation Showcase, which
highlights Canadian ingenuity at the World Congress," said Chuck
Shields, CEO of CAMRT. "Verisante Aura? has the potential to be
game-changing technology that will no doubt catch the imagination of
both our Canadian and international delegates alike."
Verisante will also have an exhibit at the convention being held at
the Sheraton Centre Toronto Hotel from June 7-9, 2012 (Booth #526).
Aura? is a non-invasive optical system that uses Raman spectroscopy to
biochemically analyze the skin, providing immediate and accurate
results. The device will help to automate the current process of
diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on
at-risk individuals, improving patient outcomes and comfort.
Early detection is key to saving the lives of melanoma patients and
saving healthcare costs. When melanoma is diagnosed and treated in the
earliest stages, the survival rate is 99 per cent and it costs about
$1,800 to treat it. In the late stages, the survival rate decreases to
15 per cent, while the cost to treat it increases to $170,000.
Aura? has been approved for sale in Canada, Europe and Australia.
About The CAMRT
Founded in 1942 by a coalition of provincial associations, the
Canadian Association of Medical Radiation Technologists (CAMRT) is
Canada's national professional association and certifying body for
medical radiation technologists and therapists across the country. As
the national professional association, the CAMRT is the national body
in a partnership with ten provincial associations who share a common
membership of approximately 12,000. CAMRT is the national organization
for the medical radiation technology profession and has the ability to
bring to the table all relevant stakeholders.
For more information on the CMART, please visit:
About Verisante Technology, Inc.
Verisante is a medical device company(http://www.verisante.com/about/)
committed to commercializing innovative systems for the early
detection of cancer(http://www.verisante.com/). The Verisante Aura?
for skin cancer detection(http://www.verisante.com/products/aura/) and
the Verisante Core? series for lung, colon and cervical cancer
detection(http://www.verisante.com/products/core/) utilize a
proprietary cancer detection platform while the operating software and
probe technology are unique to each device. The cancer detection
platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results(http://www.verisante.com/products/aura/) for many of
the most common cancers. The Aura? has been approved for sale in
Canada, Europe and Australia. The Core? has not yet been approved for
Verisante Aura? was recently awarded Popular Science Magazine's "Best
of What's New
2011, and Verisante Core? was named one of the top 10 cancer
of 2011 by the Canadian Cancer Society. In addition, the Company was
named a finalist for the 2011 Regional Awards for New
by the Canadian Manufacturers & Exporters and the National Research
Council of Canada and named as the year's top ranking Technology and
Life Sciences Company on the TSX Venture
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release.